多参数MRI对经阴道超声检出附件肿块治疗决策的影响:一种跨学科管理方法
这项前瞻性研究纳入126例经阴道超声检出不确定附件肿块的女性,在TVUS和CA-125基础上加做3T多参数MRI。mMRI单独及联合TVUS+CA-125可提高诊断敏感度和特异度,并使34%(41/126)患者的治疗决策发生改变。
要点
- 对TVUS+CA-125判断不确定的附件肿块,加做mMRI可使敏感度从86%升至97%、特异度从32%升至83%。
- mMRI联合TVUS+CA-125时敏感度100%(36/36)、特异度80%(68/90)、NPV 100%(72/72)。
- mMRI改变了34%(41/126)患者的治疗决策,其中40.7%(37/91)原建议手术者改为随访。
核心结论
- MRI可显著提高TVUS检出不确定附件肿块的诊断敏感度和特异度,其诊断信息改变了超过三分之一女性的原定治疗方案。
研究设计与样本
- 前瞻性研究,纳入126例(平均年龄54.6岁)TVUS检出不确定附件肿块并检测CA-125水平的女性。
- 所有患者加做3T多参数MRI,方案包括三平面高分辨率T2-TSE、扩散加权成像和动态对比增强。
- 分别独立评估TVUS+CA-125与mMRI的肿块性质及管理决策(随访、腹腔镜或开腹手术),再进行综合评估。
- 参考标准为手术患者的最终组织病理学,或随访患者至少24个月的随访结果。
诊断标准与关键数值
- TVUS+CA-125单独:敏感度86%(31/36)、特异度32%(29/90)、PPV 34%(31/91)、NPV 65%(29/44)。
- mMRI单独:敏感度97%(35/36)、特异度83%(75/90)、PPV 70%(35/50)、NPV 98%(75/76)。
- 三种方法联合:敏感度100%(36/36)、特异度80%(68/90)、PPV 74%(40/54)、NPV 100%(72/72)。
- 最终诊断:良性67.5%(85/126)、恶性28.6%(36/126)、交界性肿瘤4%(5/126)。
临床应用与阅片要点
- 对于TVUS+CA-125判断为不确定的附件肿块,加做mMRI有助于进一步组织定性并优化治疗计划。
- 基于TVUS+CA-125建议手术的患者中,40.7%(37/91)经mMRI发现典型良性表现而改为随访。
- 基于mMRI结果,8.7%(11/126)患者由腹腔镜改为开腹手术。
- 随访期间所有受检肿块均未出现进展或恶变。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: Adnexal masses detected incidentally at transvaginal ultrasound (TVUS) are a common and still challenging diagnostic problem. The primary goal of further imaging is an accurate tissue characterization so an optimal treatment plan can be devised including surgery only for lesions that are indeterminate or malignant. The aim of this prospective study was to evaluate the diagnostic utility of complementary multiparametric magnetic resonance imaging (mMRI) for treatment planning in patients with adnexal masses, and to assess how it ultimately correlates with subsequent histopathologic findings.
MATERIAL AND METHODS: A total of 126 women (mean age: 54.6 years) with indeterminate adnexal masses underwent mMRI at 3T in addition to TVUS and testing to determine their CA-125 levels. The mMRI protocol consisted of a high-resolution T2-TSE in three planes, diffusion weighted images and dynamic contrast enhanced. First the character of the adnexal mass and the associated management decision (follow-up, laparoscopy or laparotomy) were assessed independently for each diagnostic method (TVUS + CA-125 and mMRI). All methods were then assessed in synopsis. The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of each diagnostic method alone and in combination were calculated. The standard of reference was either final histology in women who underwent surgery or follow-up of at least 24 months in women who underwent follow-up.
RESULTS: In 67.5% (85/126) of all patients, the adnexal mass was benign; a malignant tumor was diagnosed in 28.6% (36/126) and a borderline tumor in the remaining 4% (5/126) of patients. The diagnostic indices were as follows for TVUS + CA 125 alone, mMRI alone and all three methods combined: sensitivity 86% (31/36), 97% (35/36), and 100% (36/36); specificity 32% (29/90), 83% (75/90), and 80% (68/90); PPV 34% (31/91), 70% (35/50), and 74% (40/54); and NPV 65% (29/44), 98% (75/76), and 100% (72/72). Complementary use of mMRI changed the therapeutic management decision in 34% (41/126) of all patients. In 40.7% (37/91) of patients for whom surgery had been recommended based on TVUS + CA-125, MRI revealed a typical benign finding such that those patients underwent follow-up instead of surgery. None of the examined masses exhibited (tumor) progression or malignancy during the follow-up period. A laparotomy was performed instead of a laparoscopy in 8.7% (11/126) based on the mMRI result.
CONCLUSION: MRI helps significantly improve sensitivity and specificity of diagnosis in patients with indeterminate adnexal masses detected at TVUS. Its diagnostic information revised the planned treatment in more than one-third of women.
引用
- Dirrichs T, Bauerschlag D, Maass N, et al. Impact of Multiparametric MRI (mMRI) on the Therapeutic Management of Adnexal Masses Detected with Transvaginal Ultrasound (TVUS): An Interdisciplinary Management Approach. Acad Radiol. 2020. PMID: 33293256. doi:10.1016/j.acra.2020.11.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。